Bedford Laboratories, a supplier of multisource and specialty injectable products to the US and International markets, has added Sumaptriptan Succinate injection, 6mg (base)/0.5ml pre-filled syringes to its product offerings.
Sumaptriptan Succinate injection is indicated for the acute treatment of migraine attacks with or without aura, and the acute treatment of cluster headache episodes.
Bedford Laboratories’ Sumaptriptan Succinate injection has received approval from the Food and Drug Administration and is now made available.
Bedford Laboratories claimed that Sumaptriptan Succinate injection is AP rated to Imitrex, a triptan sulfa drug containing a sulfonamide group for the treatment of migraine headaches.